Nov 08, 2023 / 09:30PM GMT
Ellie Merle - UBS - Analyst
Hi. Good afternoon, everyone. I'm Ellie Merle, one of the biotech analysts here at UBS. Very happy to have Terns Pharmaceuticals here with us today. Joining us from Terns is Mark Vignola, Chief Financial Officer; and David Strauss, Vice President of Finance.
It seems Mark has had a lot of investor meetings and is literally losing his voice. So David will be on the hot seat for these questions. But thank you, guys, so much for joining us.
Mark Vignola - Terns Pharmaceuticals, Inc. - CFO
Thanks for having us.
David Strauss - Terns Pharmaceuticals, Inc. - VP of Finance
Thank you.
Ellie Merle - UBS - Analyst
Maybe before we dive into questions, can you just -- you have a bunch of programs ongoing. Can you give us a brief high-level overview of the company and your strategy and pipeline?
David Strauss - Terns Pharmaceuticals, Inc. - VP of Finance
Yeah, that'd be great to do that. So we're
Terns Pharmaceuticals Inc at UBS BioPharma Conference Transcript
Nov 09, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers